Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market & Industry Briefs

Executive Summary

Brief summaries of recent medtech market and industry developments. This month we cover CE mark approval for Abbott's Absorb bioresorbable stent, rumors about a takeover of Smith & Nephew, and J&J's cancer detection partnership with Veridex.

You may also be interested in...



J&J Snaps Up Rare Cell Capture And Analysis Technology From Mass General

Mass General has signed a $30 million deal with two units of J&J to develop a new system for capturing and analyzing circulating tumor cells (CTCs). The collaboration aims to develop a standardized diagnostic platform for biomarker analysis of DNA, RNA, or protein from tumor cells collected noninvasively. J&J will take the indications for its current CTC system, CellSearch, and migrate them to the new platform.

TCT 2010: TAVI Takes Center Stage

In the interventional cardiology community, 2010 could certainly be considered a breakthrough year for percutaneous heart valve devices. At two major US cardiology conferences: the American College of Cardiology in the spring, and most recently, the Transcatheter Cardiovascular Therapeutics symposium, held in September, impressive results from randomized trials of transcatheter heart valve replacement/repair devices set the venues abuzz and had physicians speculating about possible near-term paradigm shifts in the way heart valve disease will be treated. The big questions now are how long it will take before these devices reach the US market, and exactly how many US patients are likely to be implanted once they are available.

The Future of Drug-Eluting Stents Part II: Biodegradable Platforms

The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. However, many researchers in this field believe the future of stenting will be defined by completely biodegradable stents that do their job of propping open the vessel until healing occurs, and gradually degrade over a period of months or years, leaving nothing permanently behind in the vessel.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT035399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel